Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: insulin aspart
INDICATION: Diabetes Mellitus
DATE: 25/04/2022
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
